Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

References

• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haematopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–e127.
   PubMed Web of Science ®Google Scholar
• Goldsmith S, Abid MB, Auletta J, et al. Post-transplant cyclophosphamide (PTCy) is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021;137(23):3291–3305.
   PubMed Web of Science ®Google Scholar
• Gaballa S, Ge I, El Fakih R, et al. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016;122(21):3316–3326.
   PubMed Web of Science ®Google Scholar
• Jorge AS, Suarez-Lledo M, Pereira A, et al. Single antigen-mismatched unrelated hematopoietic stem cell transplantation using high-dose post-transplantation cyclophosphamide is a suitable alternative for patients lacking HLA-matched donors. Biol Blood Marrow Transplant. 2018;24(6):1196–1202.
   PubMed Web of Science ®Google Scholar
• Gao XN, Lin J, Wang LJ, et al. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies. Ann Hematol. 2020;99(8):1883–1893.
   PubMed Web of Science ®Google Scholar
• Ueda M, Mielcarek MB, Sandmaier BM, et al. CMV viral load after peripheral blood stem cell transplantation (PBSCT) and posttransplant high-dose cyclophosphamide (PTCy). Biol Blood Marrow Transplant. 2019;25(93):S72–S73.
   Google Scholar
• Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173–178.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118(3):179–184.
   PubMed Web of Science ®Google Scholar
• Burns LJ, Miller W, Kandaswamy C, et al. Randomized clinical trial of ganciclovir vs. acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant. 2002;30(12):945–951.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015;162(1):1–10.
   PubMed Web of Science ®Google Scholar
• Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118(20):5689–5696.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99(8):3050–3056.
   PubMed Web of Science ®Google Scholar
• Hill JA, Pergam SA, Cox E, et al. A modified intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplantation recipients. Biol Blood Marrow Transpl. 2018;24(10):2094–2100.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Yeager AM, Chandrasekar PH, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36(6):749–758.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic cell transplantation. N Engl J Med. 2017;377(25):2433–2444.
   PubMed Web of Science ®Google Scholar
• Johnsrud JJ, Nguyen IT, Domingo W, et al. Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant. Biol Blood Marrow Transpl. 2020;26(10):1963–1970.
   PubMed Web of Science ®Google Scholar
• Lin A, Flynn J, DeRespiris L, et al. Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Transplant Cell Ther. 2021;27:85.e1–85.e6.
   PubMedGoogle Scholar
• Solomon SR, Sizemore CA, Sanacore M, et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant. 2015;21(7):1299–1307.
   PubMed Web of Science ®Google Scholar
• Symons HJ, Zahurak M, Cao Y, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4(16):3913–3925.
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137(3):420–428.
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0; 2021 [cited 2021 Aug 1]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
   Google Scholar
• Hosoi H, Murata S, Mushino T, et al. Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2020;99(10):2453–2454.
   PubMed Web of Science ®Google Scholar
• Hammerstrom AE, Lombardi LR, Pingali SR, et al. Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(2):353–358.
   PubMed Web of Science ®Google Scholar
• Vusirikala M, Wolff SN, Stein RS, et al. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant. 2001;28(3):265–270.
   PubMed Web of Science ®Google Scholar
• Anderson A, Raja M, Vazquez N, et al. Clinical “real-world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transplant. 2020;34(7):e13866.
   PubMed Web of Science ®Google Scholar
• Sharma P, Gakhar N, MacDonald J, et al. Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation. Bone Marrow Transplant. 2020;55(4):780–786.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Lazzarotto T, Bonifazi F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI Societies. Clin Transplant. 2019;33(10):e13666.
   PubMed Web of Science ®Google Scholar
• Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;135(19):1619–1629.
   PubMed Web of Science ®Google Scholar
• Camargo JF, Kimble E, Rosa R, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy and allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24(4):806–814.
   PubMed Web of Science ®Google Scholar
• Cassaniti I, Colombo AA, Bernasconi P, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021;21(4):1622–1628.
   PubMed Web of Science ®Google Scholar
• Douglas CM, Barnard R, Holder D, et al. Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients. Clin Infect Dis. 2020;221:117–126.
   Google Scholar
• Alain S, Feghoul L, Girault S, et al. Letermovir breakthroughs during the French named patient programme: interest of monitoring blood concentrations in clinical practice. J Antimicrob Chemother. 2020;75(8):2253–2257.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703–1711.
   PubMed Web of Science ®Google Scholar
• Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2021;39(18):1971–1982.
   PubMed Web of Science ®Google Scholar
• Camargo JF, Ebisu Y, Jimenez-Jimenez A, et al. Lower incidence of cytomegalovirus reactivation following post-transplantation cyclophosphamide HLA-mismatched unrelated donor transplantation. Transplant Cell Ther. 2021;27(12):1017.e1–1017.e7.
   PubMedGoogle Scholar
• Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007;110(2):490–500.
   PubMed Web of Science ®Google Scholar